Published in J Thromb Haemost on December 01, 2006
FlnA-null megakaryocytes prematurely release large and fragile platelets that circulate poorly. Blood (2011) 1.72
Migfilin, a molecular switch in regulation of integrin activation. J Biol Chem (2008) 1.68
A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med (2010) 1.45
Migfilin and filamin as regulators of integrin activation in endothelial cells and neutrophils. PLoS One (2011) 1.06
Reconstitution of the platelet glycoprotein Ib-IX complex in phospholipid bilayer Nanodiscs. Biochemistry (2011) 0.89
Site-specific phosphorylation of kindlin-3 protein regulates its capacity to control cellular responses mediated by integrin αIIbβ3. J Biol Chem (2015) 0.76
Manipulation of Cell Cycle and Chromatin Configuration by Means of Cell-Penetrating Geminin. PLoS One (2016) 0.75
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest (1999) 2.34
Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost (2011) 2.18
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med (2001) 1.75
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost (2003) 1.72
Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J (1999) 1.72
The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett (1997) 1.70
Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. Gastroenterology (1992) 1.61
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J Thromb Haemost (2010) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood (1998) 1.48
Countries' donation performance in perspective: time for more accurate comparative methodologies. Am J Transplant (2007) 1.45
The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. J Thromb Haemost (2009) 1.41
Further evidence that fibrillar collagen is unable to promote platelet shape change and aggregation in the absence of secondary agonists. J Thromb Haemost (2005) 1.40
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol (1998) 1.35
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol (1999) 1.29
Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol (2000) 1.26
The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell Mol Life Sci (2005) 1.26
CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol (1997) 1.26
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost (2005) 1.25
An endoscopic evaluation of the effects of non-steroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc (1975) 1.23
Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost (2000) 1.21
Bacterial contamination in platelet concentrates. Vox Sang (2014) 1.18
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy (2008) 1.17
The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol (1998) 1.15
The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett (2001) 1.15
Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost (1997) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood (1999) 1.14
The human platelet ADP receptor activates Gi2 proteins. Biochem J (1995) 1.12
ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 1.12
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy (2008) 1.11
BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood (2001) 1.10
Activation of ADP receptors and platelet function. Thromb Haemost (1997) 1.09
Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow. Importance of the GPib/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear. J Biol Chem (1999) 1.09
Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem (1993) 1.08
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia (2004) 1.06
The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem (1999) 1.06
CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res (1992) 1.06
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant (2009) 1.05
Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. Biochemistry (2000) 1.03
Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents (2001) 1.03
Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol (2001) 1.02
Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. Blood (2001) 1.02
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1996) 1.01
ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes--an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost (1992) 0.99
Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol (2002) 0.99
Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost (2011) 0.99
A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. J Thromb Haemost (2005) 0.99
Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol (1987) 0.97
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost (1991) 0.97
Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene (1996) 0.96
Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. J Leukoc Biol (1996) 0.96
Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost (2004) 0.94
The alpha(IIb)beta(3) integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. Blood (2000) 0.94
Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem (1999) 0.94
Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood (2001) 0.94
The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost (2012) 0.94
The kinetics of translocation and cellular quantity of protein kinase C in human leukocytes are modified during spaceflight. FASEB J (1999) 0.93
Cytoskeletal regulation of the platelet glycoprotein Ib/V/IX-von willebrand factor interaction. Blood (2000) 0.93
A general approach to the generation of monoclonal antibodies against members of the tetraspanin superfamily using recombinant GST fusion proteins. J Immunol Methods (1999) 0.93
Cytogenetic aspects of B-cell chronic lymphocytic leukemia: their correlation with clinical stage and different polyclonal mitogens. Cancer Genet Cytogenet (1987) 0.92
Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost (2003) 0.92